Intarcia terminates late-stage diabetes trials

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials evaluating ITCA 650 in Type II diabetes, according to ClinicalTrials.gov.

Read the full 195 word article

User Sign In